The tumor size was significantly reduced by NAC in UGT1A1-poly patients (77.5 %) compared with UGT1A1-wild patients (49.5 %, p < 0.05), although there were no differences in severe adverse events between them (Table 4). This evidence concerns the gene UGT1A1 and neoplasm.